Follow Mary Nash Stoddard on Twitter

Monday, October 11, 2010

Kidney/Bone-Marrow/Lymph Nodes/Brain Tumors from Aspartame Study

Since the FOX TV report aired in Washington in the fall of 1999, more studies have been published showing aspartame should be re-called and re-tested as a drug:

In Vivo. 2007 Jan-Feb;21(1):89-92.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17354619&query_hl=2&itool=pubmed_DocSum 

The effect of aspartame administration on oncogene and suppressor gene expressions.
Gombos KVarjas TOrsos ZPolyak E,  Peredi JVarga ZNowrasteh G,
Tettinger A,  Mucsi GEmber I.

Faculty of Medicine, Institute of Public Health University of Pecs, Pecs, Hungary.
BACKGROUND: Aspartame (L-phenylalanineN-L-alpha-aspartyl-1-methyl ester) is an artificial sweetener withwidespread applications. Previously published results have shown that among rats receiving aspartame a significant increase of lymphoreticular neoplasms, brain tumours and transitional cell tumours occurred. The aim of our short-term experiment was to investigate the biological effect of aspartame consumption by determining the expressions of key oncogenes and a tumour suppressor gene.

MATERIALS AND METHODS: After one week per os administration of various doses ofaspartame to CBA/CA female mice, p53, c-myc, Ha-ras gene expression alterations were determined in individual organs.

RESULTS: The results showed an increase in gene expressions concerning all the investigated genes especially in organs with a high proliferation rate:lymphoreticular organs, bone-marrow and kidney. 

CONCLUSION: Aspartame has a biological effect even at the recommended daily maximum dose. 
_______________________________________________________________________
Mary Nash Stoddard, Founder
Aspartame Consumer Safety Network and Pilot Hotline
[Promoting FDA Recall of Aspartame - since 1987]
P.O. Box 2001 - Frisco,  TX 75034 - U.S. 
phone: 1-214-387-4001
email: marystod@airmail.net
http://www.aspartamesafety.com